Please login to the form below

Not currently logged in
Email:
Password:

medicines optimisation

This page shows the latest medicines optimisation news and features for those working in and with pharma, biotech and healthcare.

NHS seeks 'solution creators' from within pharma

NHS seeks 'solution creators' from within pharma

There has also been “a degree of convergence”among the people and bodies that work on assessing new medicines, he added, whether they be involved with NICE, the Cancer Drugs Fund ... However, a warning note about partnership working was sounded by

Latest news

  • Pharma could make more of its real world evidence Pharma could make more of its real world evidence

    But pharmaceutical companies do – and they are perfectly placed to help the NHS improve medicines optimisation. ... In reality, many pharma companies have adapted their operations to develop processes and strategies to collect RWE for their medicines.

  • Industry pays £310m to underwrite medicines bills Industry pays £310m to underwrite medicines bills

    Industry agreed to the PPRS in order to improve the use of innovative medicines in the UK. ... We are working with the Department of Health, NHS England and government to ensure action in key areas such as changes to NICE's decision making framework and

  • Patients should have a say in their medication, claims NICE Patients should have a say in their medication, claims NICE

    Paul Chrisp, programme director for the medicines and prescribing centre at NICE, said: “ The NICE guideline on medicines optimisation sets out what needs to be done by all health and social ... Medicines optimisation is not a new concept. “ This

  • ABPI: Put value-based assessment back on the agenda ABPI: Put value-based assessment back on the agenda

    What has happened to the PPRS money is a good question,” he said, adding: “ It could be spent on initiatives which help ensure that we are using UK medicines appropriately.”. ... The ABPI is already working with NHS England on a joint medicines

  • Janssen will cover cost of unsuccessful hepatitis C treatment Janssen will cover cost of unsuccessful hepatitis C treatment

    The company's' UK medical director Peter Barnes described the scheme as a great example of medicines optimisation – an increasing priority for the NHS. “

More from news
Approximately 11 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • How AbbVie Care is putting patients at the centre How AbbVie Care is putting patients at the centre

    Industry must assume a responsibility to move beyond just the manufacture of medicines. ... Create a reliable supply chain ensuring that patients get the right medicine at the right time, supporting medicines optimisation.

  • It's time to get diabetes right It's time to get diabetes right

    All with negative implications for patients - but to date focusing on specialist medicines. ... It is clear that the medicines optimisation agenda is of more importance now than ever.

  • Communicating value Communicating value

    In England the NHS-driven Medicines Optimisation programme will this year engage local payers and providers on the ability of good medicines usage to improve patient adherence and outcomes and reduce ... But marketers need to find differentiators for

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ABPI names NHS partnership manager ABPI names NHS partnership manager

    In his new role, he will manage the four ABPI regional partnership managers and lead ABPI activities in academic health science networks and medicines optimisation. ... ensure appropriate medicines and technologies are available to all eligible

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics